Clinical Trial Update: A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the Ad5.F35-hGCC-PADRE cancer vaccine for pancreatic, colorectal, gastric, and esophageal adenocarcinomas; the sponsor is Thoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Adenocarcinoma
• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Ad5.F35-hGCC-PADRE

Snippet

Sponsor: Thomas Jefferson University | Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING